Semaglutide linked to risk of rare eye condition An observational US study suggests a potential risk of nonarteritic anterior ischaemic optic neuropathy (NAION) associated with prescriptions for the GLP-1 agonist semaglutide
By mimicking this hormone, semaglutide drastically reduces appetite and caloric intake
Weeks 25 through 52: maintenance and optimization Nutrition priorities: As weight loss slows, caloric intake should stabilize rather than continuing to decrease
Ornellas F, Mello VS, Mandarim-de-Lacerda CA, Aguila MB
Semaglutide is a revolutionary new medication that mimics the effects of a hormone called GLP-1 in the body, which helps to regulate appetite and food intake
One of the innovative solutions we offer is the integration of Semaglutide GLP-1 with other weight loss and aesthetic procedures to optimize results for our clients